Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 816,000 shares, a decrease of 12.0% from the April 30th total of 926,900 shares. Based on an average trading volume of 297,900 shares, […]
SAN DIEGO, June 4, 2024 /PRNewswire/ Halozyme Therapeutics, Inc. today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the.
/PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Risk and Volatility TScan Therapeutics has a […]
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends. Risk and Volatility TScan Therapeutics has a […]